TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 130 filers reported holding TCR2 THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $48 | -65.7% | 31,683 | -77.4% | 0.00% | – |
| Q4 2022 | $140 | -100.0% | 140,041 | -47.8% | 0.00% | – |
| Q3 2022 | $483,000 | -47.7% | 268,130 | -15.8% | 0.00% | -100.0% |
| Q2 2022 | $923,000 | +235.6% | 318,416 | +220.1% | 0.00% | – |
| Q1 2022 | $275,000 | -95.9% | 99,469 | -93.1% | 0.00% | -100.0% |
| Q4 2021 | $6,735,000 | +113.2% | 1,445,317 | +289.4% | 0.00% | +200.0% |
| Q3 2021 | $3,159,000 | +245.2% | 371,167 | +565.1% | 0.00% | – |
| Q2 2021 | $915,000 | -72.1% | 55,807 | -62.4% | 0.00% | -100.0% |
| Q1 2021 | $3,275,000 | -78.6% | 148,343 | -70.0% | 0.00% | -81.8% |
| Q4 2020 | $15,308,000 | +13.9% | 494,928 | -25.1% | 0.01% | -35.3% |
| Q3 2020 | $13,434,000 | +2091.5% | 661,101 | +1555.6% | 0.02% | +1600.0% |
| Q2 2020 | $613,000 | +11.5% | 39,930 | -43.8% | 0.00% | 0.0% |
| Q1 2020 | $550,000 | -23.3% | 71,098 | +41.6% | 0.00% | 0.0% |
| Q4 2019 | $717,000 | -64.6% | 50,212 | -64.5% | 0.00% | -66.7% |
| Q2 2019 | $2,024,000 | -51.7% | 141,435 | -41.2% | 0.00% | -50.0% |
| Q1 2019 | $4,194,000 | – | 240,638 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $4,046,814 | 1.69% |
| MPM BioImpact LLC | 3,370,982 | $3,367,611 | 0.87% |
| TANG CAPITAL MANAGEMENT LLC | 2,738,947 | $2,735,660 | 0.40% |
| Newtyn Management, LLC | 1,075,000 | $1,073,710 | 0.22% |
| HARBOR CAPITAL ADVISORS, INC. | 68,230 | $68,148 | 0.07% |
| Artal Group S.A. | 750,000 | $749 | 0.04% |
| Oasis Management Co Ltd. | 200,000 | $199,760 | 0.04% |
| Redmile Group, LLC | 731,379 | $730,501 | 0.03% |
| X-Square Capital, LLC | 31,919 | $32 | 0.02% |
| CORNERCAP INVESTMENT COUNSEL INC | 68,035 | $67,953 | 0.01% |